Atara Biotherapeutics (ATRA) Equity Average (2022 - 2025)
Historic Equity Average for Atara Biotherapeutics (ATRA) over the last 4 years, with Q3 2025 value amounting to -$35.8 million.
- Atara Biotherapeutics' Equity Average rose 6441.29% to -$35.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$35.8 million, marking a year-over-year increase of 6441.29%. This contributed to the annual value of -$98.3 million for FY2024, which is 81696.89% down from last year.
- Latest data reveals that Atara Biotherapeutics reported Equity Average of -$35.8 million as of Q3 2025, which was up 6441.29% from -$45.1 million recorded in Q2 2025.
- Atara Biotherapeutics' Equity Average's 5-year high stood at $240.9 million during Q2 2022, with a 5-year trough of -$104.6 million in Q2 2024.
- Over the past 4 years, Atara Biotherapeutics' median Equity Average value was -$40.4 million (recorded in 2025), while the average stood at $7.2 million.
- Its Equity Average has fluctuated over the past 5 years, first tumbled by 38886.13% in 2024, then soared by 6441.29% in 2025.
- Atara Biotherapeutics' Equity Average (Quarter) stood at $156.9 million in 2022, then plummeted by 147.83% to -$75.0 million in 2023, then fell by 25.16% to -$93.9 million in 2024, then skyrocketed by 61.84% to -$35.8 million in 2025.
- Its Equity Average was -$35.8 million in Q3 2025, compared to -$45.1 million in Q2 2025 and -$76.2 million in Q1 2025.